Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 391 to 405 of 1032 results for drug therapy

  1. Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

    Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.

  2. Pancreatic cancer in adults: diagnosis and management (NG85)

    This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

  3. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

  4. Cancer services for children and young people (QS55)

    This quality standard covers providing and organising cancer services for babies, children and young people (from birth to 24 years, although the upper age limit may vary). It describes high-quality care in priority areas for improvement.

  5. Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)

    NICE has developed a medtech innovation briefing (MIB) on Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome .

  6. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

  7. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

  8. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

  9. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

  10. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)

    Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.

  11. Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)

    Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults

  12. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.

  13. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

    Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.

  14. Alpha-Stim AID for anxiety disorders (MTG56)

    Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.

  15. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB315)

    NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .